Rowe N H, Brooks S L, Young S K, Spencer J, Petrick T J, Buchanan R A, Drach J C, Shipman C
Oral Surg Oral Med Oral Pathol. 1979 Feb;47(2):142-7. doi: 10.1016/0030-4220(79)90169-5.
Seventy-six participants were enrolled in a clinical trial to determine therapeutic effectiveness of 3 percent vidarabine applied topically to recurrent perioral herpetic lesions. Following a 6- to- 12-month natural history phase, a 12-month clinical trial was conducted. Seventy participants developed 463 lesions during 361 episodes. Three percent vidarabine in a water-miscible gel was applied six times daily for 7 days to each lesion in the experimental group. Identically packaged placebo was used by the control group. Group assignment was by computer-generated randomization. Lesion size was reduced when vidarabine, rather than placebo, was applied. The difference was statistically significant (Student's t test, P = 0.02). Vesiculation followed tingling more rapidly when vidarabine, rather than placebo, was applied prior to vesiculation (P = 0.05). No significant difference between the two groups was found in episode frequency or lesion duration. Adverse reactions to vidarabine were not experienced.
76名参与者被纳入一项临床试验，以确定局部应用3%阿糖腺苷治疗复发性口周疱疹性损害的疗效。在为期6至12个月的自然病程阶段之后，进行了一项为期12个月的临床试验。70名参与者在361次发作期间出现了463处损害。在实验组中，将3%阿糖腺苷溶于水溶性凝胶中，每天对每个损害涂抹6次，持续7天。对照组使用包装相同的安慰剂。通过计算机生成随机数进行分组。应用阿糖腺苷而非安慰剂时，损害大小减小。差异具有统计学意义（Student t检验，P = 0.02）。在出现水疱之前应用阿糖腺苷而非安慰剂时，刺痛后出现水疱的速度更快（P = 0.05）。两组在发作频率或损害持续时间方面未发现显著差异。未出现对阿糖腺苷的不良反应。
